BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 16866904)

  • 1. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
    Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
    Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin therapy in Alzheimer's disease.
    Sparks DL; Sabbagh M; Connor D; Soares H; Lopez J; Stankovic G; Johnson-Traver S; Ziolkowski C; Browne P
    Acta Neurol Scand Suppl; 2006; 185():78-86. PubMed ID: 16866915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
    Feldman HH; Doody RS; Kivipelto M; Sparks DL; Waters DD; Jones RW; Schwam E; Schindler R; Hey-Hadavi J; DeMicco DA; Breazna A;
    Neurology; 2010 Mar; 74(12):956-64. PubMed ID: 20200346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for the treatment of dementia.
    McGuinness B; O'Hare J; Craig D; Bullock R; Malouf R; Passmore P
    Cochrane Database Syst Rev; 2010 Aug; (8):CD007514. PubMed ID: 20687089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT).
    Sparks DL; Petanceska S; Sabbagh M; Connor D; Soares H; Adler C; Lopez J; Ziolkowski C; Lochhead J; Browne P
    Curr Alzheimer Res; 2005 Dec; 2(5):527-39. PubMed ID: 16375656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
    Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
    Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins for the treatment of dementia.
    McGuinness B; Craig D; Bullock R; Malouf R; Passmore P
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD007514. PubMed ID: 25004278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.
    Sano M; Bell KL; Galasko D; Galvin JE; Thomas RG; van Dyck CH; Aisen PS
    Neurology; 2011 Aug; 77(6):556-63. PubMed ID: 21795660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
    Diepeveen SH; Verhoeven GW; Van Der Palen J; Dikkeschei LD; Van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF
    J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
    Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
    Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
    Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
    Vansant G; Mertens A; Muls E
    Acta Cardiol; 2001 Jun; 56(3):149-54. PubMed ID: 11471927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.